Canaccord cuts Merit Medical stock price target on acquisition impact By Investing.com

Merit Medical is acquiring View Point Medical for approximately $140M (initial $90M cash plus two $25M deferred payments); the deal is expected to add $2–4M revenue in 2026 and $14–16M in 2027 and be accretive to non‑GAAP EPS by 2027. Canaccord cut its price target to $90 (from $99) and trimmed 2026 adjusted EPS to $4.00 (from $4.05) while modestly raising revenue estimates; BTIG reiterated a $107 PT but Wells Fargo downgraded to Equal Weight citing fiscal‑2026 guidance uncertainty. The transaction includes roughly $2M of lower interest income and excludes about $5.3M of one‑time transaction expenses; Merit also struck an exclusive Medtronic distribution deal for the FDA‑cleared ViaVerte system with undisclosed financial terms.

Analysis

This transaction and the Medtronic distribution create a binary two-year path: either Merit leverages a larger OEM channel to convert niche procedure-level sales into scalable recurring revenue, or it absorbs integration and working-capital drag that pushes margin recovery beyond the market’s 12–18 month horizon. The market’s split view (some houses staying bullish while others trim ratings) reflects asymmetric information about execution risk — commercial uptake of a new procedure is lumpy and concentrated in a few high-volume accounts, so near-term guidance volatility is likely even if medium-term economics are attractive.

Second-order supply-chain effects matter: tying commercial access to a large distributor reduces Merit’s go-to-market friction but increases dependency on third‑party inventory allocation and pricing cadence. That raises the probability of quarter-to-quarter revenue lumpiness as Medtronic prioritizes SKUs, and it creates leverage to Medtronic’s procurement and contract teams that could compress realized prices in later contract renewals. Competing small-cap device makers without such distribution deals face increased pricing pressure and may need to either discount or accelerate their own tuck-ins.

Key risks and catalysts are execution of integration, timing of reimbursement adoption for the new procedure, and the timing/size of one‑off charges that affect free cash flow. Near-term (days–weeks) the trigger is any guidance update or incremental disclosure on commercial roll‑out; medium-term (6–18 months) the test is measured adoption across the top 20 accounts and margin trajectory; longer-term (2+ years) the question is whether the deal meaningfully shifts cumulative revenue per rep and lowers customer acquisition cost enough to sustain >15% growth rates.

Key Decisions for Investors

• Long MMSI via a defined-risk call-spread (9–12 month expiry): target a 25–40% upside rerating on successful integration; max loss = premium paid. Entry on any post-earnings weakness when volatility spikes above the stock’s 90‑day average.
• Pair trade to express idiosyncratic upside: long MMSI equity + short a small-cap medtech basket (or ETF) to neutralize macro/sector moves; size the short to cap portfolio beta and keep net exposure biased toward stock-specific outcomes over 6–12 months.
• Buy short-dated (30–90 day) protection ahead of the next guidance/earnings release if you hold or plan to build a position — put cost is cheap insurance against a guidance-driven selloff that would present a better entry for longer-duration trades.
• If already long and seeking yield, sell 6–12 week covered calls to monetize elevated volatility while awaiting clearer integration proof points; cap upside but fund downside hedges and transaction-related cash drag.